Quarter
Charts

ResMed Inc.

RMD

CIK 0000943819 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$1.42B
↑+11.0% +$141Mvs FY2024 (Q4)
Operating Income
$492M
↑+17.8% +$74Mvs FY2024 (Q4)
Net Income
$393M
↑+13.9% +$48Mvs FY2024 (Q4)
Gross Profit
$879M
↑+17.0% +$127Mvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Strong
76/100
  • Profitability
    90ROIC 23.1% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 3.44 (above 1.5 = solid)
  • Leverage
    94D/E 0.11 (under 0.5 = conservative)
  • Efficiency
    37Asset Turnover 0.68x (1.0+ = capital-efficient)
  • Growth
    53Revenue YoY +11.0% (10% = solid, 25%+ = elite)
  • Margin Trend
    84Op Margin 34.6% · trend +2.0pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

DCF intrinsic value

DCF intrinsic value

two-stage Gordon model

Project RMD's free cash flow forward, discount back at your hurdle rate, divide by diluted shares. Edit the assumptions to see how sensitive the intrinsic value is.

25%

Trailing 3-yr CAGR was 97.3%

10%

10% is a common all-equity benchmark for US large-caps

2.5%

Should be ≤ long-run GDP growth (~2.5% nominal)

5

5-year explicit projection + perpetuity terminal

Intrinsic value per share
$376.18
Total enterprise IV
$55.43B
Diluted shares
0.15B
Terminal PV
$43.03B (78% of total)
Year-5 FCF
$5.07B
YearProjected FCFDiscounted PV
+1$2.08B$1.89B
+2$2.60B$2.15B
+3$3.25B$2.44B
+4$4.06B$2.77B
+5$5.07B$3.15B
Terminal$69.31B$43.03B

DCF outputs are HIGHLY sensitive to growth + WACC assumptions. A 1pp WACC change can shift IV by 20%+. Use this as a sanity-check vs market price, not a target — and always cross-check the underlying FCF source (EDGAR cashflow statement, latest annual). Margin of safety convention: 30-50% discount to IV before buying.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$123M
investment in PP&E
Dividends paid (TTM)
$331M
cash returned to holders
Stock buybacks (TTM)
$500M
share count reduction
Stock-based comp (TTM)
$99M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$8.50B
everything owned
Total liabilities
$2.18B
everything owed
Stockholders' equity
$6.32B
shareholder claim
Net debt
$-1.01B
Net cash position ($1.01B)

Recent performance · 66 quarters

Revenue↑+11.0% +$141M
$1.42B
Net Income↑+13.9% +$48M
$393M
Free Cash Flow↑+8.1% +$23M
$311M
Operating Margin↑+2.0pts
34.6%

Drill down

RMD Sankey

See ResMed Inc.'s revenue flow into every line item of the income statement and balance sheet — every dollar accounted for, with prior-period comparison.

Open Sankey

RMD Charts

66 quarters of historical line items — Income, Cash Flow, Balance Sheet, plus margins. Click any chart for the trend dialog.

Open Charts

RMD Key Metrics

EPS, BVPS, FCF/Share, ROE, ROA, ROIC, D/E, Current Ratio, Quick Ratio, Asset Turnover — 10 CFA-grade fundamentals derived from EDGAR data.

Open Key Metrics